Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Histone deacetylase inhibitor chidamide regulates the Wnt/β-catenin pathway by MYCN/DKK3 in B-ALL

Investigational New Drugs(2021)10.1007/s10637-021-01079-5Source: DataRank Database

Histone deacetylase inhibitor chidamide regulates the Wnt/β-catenin pathway by MYCN/DKK3 in B-ALL is a research paper published in Investigational New Drugs (2021). On theSindex it has a DataRank of 0.557. It has been cited 40 times.

N/A

0.557DataRank · unranked

Scored on demand from live citation data

40 citations

Download PDF

Cite:

Linked data & code

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (2 grants)Impact (FWCI 7.03)OA: closedTopics (57)Linked Datasets (25)DataCite Reuse (25)IDs (PubMed, OpenAlex)

FAIR Checklist

Context only (not used in score)

Findable (2/2)

Has DOI
Indexed in repositories

Accessible (0/2)

Interoperable (2/2)

DataCite relations
Linked datasets

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 100%Citation Network 0%

Base Score Contribution

0.557

From this paper's citation signal

Citation Network Contribution

Citation network not refreshed for this result

This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.

Learn more about DataRank methodology →

Authors (14)

Chengfang Lv,Lili Sun,Qi Li ORCID,Yuhuang Wang,Min Wu ORCID

Live enrichment

PubMed:33566253 OpenAlex:https://openalex.org/W3126958487

Scientific Research and Innovation Fund of the First affiliated Hospital of Harbin Medical University

Grant: 2020B15

Foundation for the Dean of Southern University of Science and Technology Hospital in 2020

Grant: 2020-A3

FWCI

7.03

Citation Percentile

1.0%

Citation Trend

2022

2023

2024

2025

2026

closedLicense: https://www.springernature.com/gp/researchers/text-and-data-mining

publisherhttps://link.springer.com/content/pdf/10.1007/s10637-021-01079-5.pdf

publisherhttps://link.springer.com/article/10.1007/s10637-021-01079-5/fulltext.html

journalhttps://doi.org/10.1007/s10637-021-01079-5

repositoryhttps://pubmed.ncbi.nlm.nih.gov/33566253

Fields of Study

Acute Lymphoblastic Leukemia researchChildhood Cancer Survivors' Quality of LifeHistone Deacetylase Inhibitors ResearchMedicineBiologyAdaptor Proteins, Signal TransducingAminopyridinesAnimalsBenzamidesCell Line, TumorCell ProliferationGene Expression Regulation, NeoplasticHistone Deacetylase InhibitorsHumansMiceMice, Inbred NODMice, SCIDN-Myc Proto-Oncogene ProteinPrecursor Cell Lymphoblastic Leukemia-LymphomaWnt Signaling PathwayXenograft Model Antitumor Assays

MeSH Terms

N-Myc Proto-Oncogene ProteinAminopyridinesAnimalsBenzamidesHumansGene Expression Regulation, NeoplasticMice, SCIDMice, Inbred NODXenograft Model Antitumor AssaysCell Line, TumorAdaptor Proteins, Signal TransducingCell ProliferationMicePrecursor Cell Lymphoblastic Leukemia-LymphomaHistone Deacetylase InhibitorsWnt Signaling Pathway

Keywords

Wnt signaling pathwayHistone deacetylaseHistone deacetylase inhibitorAcetylationCancer researchCateninBiologyHDAC1HistoneCell growthHistone deacetylase 2Signal transductionCell biologyBiochemistryGeneMycnDkk3Wnt/β-cateninChidamideB Cell Acute Lymphocytic Leukaemia

Additional file 1 of Low expression of miR-182 caused by DNA hypermethylation accelerates acute lymphocyte leukemia development by targeting PBX3 and BCL2: miR-182 promoter methylation is a predictive marker for hypomethylation agents + BCL2 inhibitor venetoclax

10.6084/m9.figshare.25478778.v1figshare

10.6084/m9.figshare.25478778figshare

Additional file 2 of Low expression of miR-182 caused by DNA hypermethylation accelerates acute lymphocyte leukemia development by targeting PBX3 and BCL2: miR-182 promoter methylation is a predictive marker for hypomethylation agents + BCL2 inhibitor venetoclax

10.6084/m9.figshare.25479136.v1figshare

10.6084/m9.figshare.25479136figshare

Additional file 3 of Low expression of miR-182 caused by DNA hypermethylation accelerates acute lymphocyte leukemia development by targeting PBX3 and BCL2: miR-182 promoter methylation is a predictive marker for hypomethylation agents + BCL2 inhibitor venetoclax

10.6084/m9.figshare.26697818.v1figshare

10.6084/m9.figshare.26697818figshare

Additional file 10 of Low expression of miR-182 caused by DNA hypermethylation accelerates acute lymphocyte leukemia development by targeting PBX3 and BCL2: miR-182 promoter methylation is a predictive marker for hypomethylation agents + BCL2 inhibitor venetoclax

10.6084/m9.figshare.26697839.v1figshare

10.6084/m9.figshare.26697839figshare

Additional file 13 of Low expression of miR-182 caused by DNA hypermethylation accelerates acute lymphocyte leukemia development by targeting PBX3 and BCL2: miR-182 promoter methylation is a predictive marker for hypomethylation agents + BCL2 inhibitor venetoclax

10.6084/m9.figshare.26697848.v1figshare

Additional file 14 of Low expression of miR-182 caused by DNA hypermethylation accelerates acute lymphocyte leukemia development by targeting PBX3 and BCL2: miR-182 promoter methylation is a predictive marker for hypomethylation agents + BCL2 inhibitor venetoclax

10.6084/m9.figshare.26697851.v1figshare

Additional file 12 of Low expression of miR-182 caused by DNA hypermethylation accelerates acute lymphocyte leukemia development by targeting PBX3 and BCL2: miR-182 promoter methylation is a predictive marker for hypomethylation agents + BCL2 inhibitor venetoclax

10.6084/m9.figshare.26697845.v1figshare

10.6084/m9.figshare.26697851figshare

10.6084/m9.figshare.26697845figshare

10.6084/m9.figshare.26697848figshare

Additional file 11 of Low expression of miR-182 caused by DNA hypermethylation accelerates acute lymphocyte leukemia development by targeting PBX3 and BCL2: miR-182 promoter methylation is a predictive marker for hypomethylation agents + BCL2 inhibitor venetoclax

10.6084/m9.figshare.26697842.v1figshare

10.6084/m9.figshare.26697842figshare

Additional file 5 of Low expression of miR-182 caused by DNA hypermethylation accelerates acute lymphocyte leukemia development by targeting PBX3 and BCL2: miR-182 promoter methylation is a predictive marker for hypomethylation agents + BCL2 inhibitor venetoclax

10.6084/m9.figshare.26697824figshare

Additional file 6 of Low expression of miR-182 caused by DNA hypermethylation accelerates acute lymphocyte leukemia development by targeting PBX3 and BCL2: miR-182 promoter methylation is a predictive marker for hypomethylation agents + BCL2 inhibitor venetoclax

10.6084/m9.figshare.26697827figshare

Additional file 9 of Low expression of miR-182 caused by DNA hypermethylation accelerates acute lymphocyte leukemia development by targeting PBX3 and BCL2: miR-182 promoter methylation is a predictive marker for hypomethylation agents + BCL2 inhibitor venetoclax

10.6084/m9.figshare.26697836figshare

Additional file 7 of Low expression of miR-182 caused by DNA hypermethylation accelerates acute lymphocyte leukemia development by targeting PBX3 and BCL2: miR-182 promoter methylation is a predictive marker for hypomethylation agents + BCL2 inhibitor venetoclax

10.6084/m9.figshare.26697830figshare

Histone deacetylase inhibitor chidamide regulates the Wnt/β-catenin pathway by MYCN/DKK3 in B-ALL

FAIR Checklist

DataRank Breakdown

Authors (14)

Funding (2 grants)

Impact

Open Access

Topics

Linked Datasets (25)